Open AccessThe impact of revised CLSI cefazolin breakpoints on the clinical outcomes of Escherichia coli bacteremia
Author(s) -
Kung-Ching Wang,
Meei-Fang Liu,
Chin-Fu Lin,
ZhiYuan Shi
Publication year - 2015
Publication title -
journal of microbiology immunology and infection
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.223
H-Index - 57
eISSN - 1995-9133
pISSN - 1684-1182
DOI - 10.1016/j.jmii.2015.08.017
Subject(s) - bacteremia , cefazolin , medicine , escherichia coli , microbiology and biotechnology , breakpoint , biology , antibiotics , genetics , gene , chromosomal translocation
The susceptibility breakpoints of cephalosporins for Enterobacteriaceae were revised by the Clinical and Laboratory Standards Institute (CLSI) in 2010 and 2011. The clinical outcome and susceptibility data were analyzed to evaluate the impact of revised CLSI cefazolin breakpoints on the treatment of Escherichia coli bacteremia.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom